Answer
Cabozantinib inhibits MET (hepatocyte growth factor receptor), VEGF (vascular endothelial growth factor) receptors, RET, AXL (GAS6 receptor), KIT (stem cell factor receptor), and FLT3 (Fms-like tyrosine kinase-3).
Sources for this answer
- COMETRIQ 20 & 80 mg hard capsulesIpsen Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 16Document updated
Sources checked